DUBLIN--(BUSINESS WIRE)--The 'Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023-2030' report has been added to ResearchAndMarkets.com's offering.

都柏林-（商业线）--“亨廷顿舞蹈病治疗市场规模，按治疗（对症治疗，疾病改善疗法），按最终用途，按地区和细分预测，2023-2030年”报告已添加到ResearchAndMarkets.com的产品中。

The anticipated growth of the global Huntington's disease treatment market is poised to make a significant impact, with projections indicating it will reach a substantial USD 1,871.2 million by 2030, as detailed in this comprehensive report. The market's trajectory is set to experience a robust Compound Annual Growth Rate (CAGR) of 23.20% from 2023 to 2030..

全球亨廷顿舞蹈病治疗市场的预期增长有望产生重大影响，预计到2030年将达到1.871亿美元，详见本综合报告。从2023年到2030年，市场的发展轨迹将经历23.20%的强劲复合年增长率（CAGR）。。

This remarkable growth is attributed to multifaceted factors, including substantial research and development investments for pioneering new product developments, collaborative research endeavors, and the pronounced burden of Huntington's disease (HD) in western nations. Huntington's disease, a rare inherited neurodegenerative condition, exerts its impact across multiple generations, severely affecting individuals between the ages of 30 and 50.

这种显着的增长归因于多方面的因素，包括对开创性新产品开发的大量研究和开发投资，合作研究努力以及西方国家亨廷顿舞蹈病（HD）的明显负担。亨廷顿舞蹈病是一种罕见的遗传性神经退行性疾病，在多代人中发挥作用，严重影响30至50岁的个体。

This debilitating disorder impairs their ability to engage in work, fulfill familial responsibilities, and even accomplish routine tasks..

这种使人衰弱的疾病削弱了他们从事工作，履行家庭责任甚至完成日常任务的能力。。

The disease's prevalence showcases a striking variability of more than ten-fold across different geographical regions. This variation could be linked to differences in case identification techniques and diagnostic criteria. Remarkably, the Asian population consistently exhibits a lower prevalence, whereas Europe, North America, and Australia grapple with a higher prevalence..

该疾病的患病率在不同地理区域显示出超过10倍的显着变异性。这种变化可能与病例识别技术和诊断标准的差异有关。值得注意的是，亚洲人口的患病率一直较低，而欧洲，北美和澳大利亚的患病率较高。。

Key industry players, including Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are directing their efforts toward groundbreaking research and development of symptomatic therapies targeting HD. Azevan Pharmaceuticals is vigorously developing SRX246, an experimental drug designed to address neuropsychiatric symptoms linked with Huntington's disease.

包括Neurocrine Biosciences，Inc。和Azevan Pharmaceuticals，Inc。在内的主要行业参与者正在努力开创性地研究和开发针对HD的症状疗法。Azevan Pharmaceuticals正在大力开发SRX246，这是一种旨在解决与亨廷顿舞蹈病相关的神经精神症状的实验药物。

Functioning by inhibiting the vasopressin 1a (V1a) receptor in the brain, SRX246 holds potential in curbing the manifestation of irritable and aggressive behavior often seen in HD patients..

SRX246通过抑制大脑中的加压素1a（V1a）受体发挥功能，具有抑制HD患者常见的易怒和攻击行为表现的潜力。。

Despite the advancements, it's noteworthy that currently approved medications offer symptomatic and palliative care, lacking the capacity to tackle the underlying cause of the ailment. While these drugs can mitigate symptom severity, their usage is occasionally linked to undesirable effects such as somnolence, gait complications, dysphagia, and apathy—factors that significantly affect the patient's quality of life..

尽管取得了进展，但值得注意的是，目前批准的药物提供对症和姑息治疗，缺乏解决疾病根本原因的能力。虽然这些药物可以缓解症状的严重程度，但它们的使用偶尔会与不良影响相关，如嗜睡，步态并发症，吞咽困难和显着影响患者生活质量的冷漠因素。。

As the quest for a cure continues, the assessment of Health-related Quality of Life (HRQOL) remains pivotal in the evaluation of its impact on patients. Addressing the needs of patients in the early to middle stages of the disease entails the provision of comprehensive multidisciplinary healthcare services, encompassing cognitive function evaluation and counseling..

随着寻求治疗的继续，健康相关生活质量（HRQOL）的评估仍然是评估其对患者影响的关键。在疾病的早期至中期满足患者的需求需要提供全面的多学科医疗服务，包括认知功能评估和咨询。。

However, the journey of drug development for HD has encountered significant hurdles, with numerous therapies failing to demonstrate efficacy or showing pronounced toxicity. A prime example is Vaccinex Inc.'s phase II trial of Pepinemab, which failed to meet pre-specified co-primary endpoints for early manifest and prodromal HD patients..

然而，HD的药物开发之旅遇到了重大障碍，许多疗法未能证明疗效或显示出明显的毒性。一个主要的例子是Vaccinex Inc.的Pepinemab II期临床试验，未能达到早期明显和前驱HD患者的预先指定的共同主要终点。。

Huntington's Disease Treatment Market Report Highlights

The symptomatic treatment segment accounted for the largest revenue share in 2022 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD

由于产品可用性和专利保护，对症治疗部分在2022年占最大的收入份额。由于SAGE-718和Cellavita HD的进入，预计疾病改善疗法将成为预测年份中增长最快的部分

Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein

公司现在正致力于开发可以直接注射到大脑中以直接抑制突变HTT蛋白形成的治疗方法，而不是针对突变蛋白

Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy)

具有早期开发新靶点的药物包括Cellavita和Azidus Brazil的Cellavita HD（干细胞疗法），Sangamo Therapeutics，Inc。mHTT-ZFP（锌指蛋白）和UniQure的AMT-130（基因疗法）

North America held the highest revenue share in 2022 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada

北美在2022年占有最高的收入份额，由于更好的报销设施以及美国和加拿大高清的高负担，预计将在预测期间占据市场主导地位

Market Dynamics

市场动态

Market Driver Analysis

市场驱动因素分析

Strong Product Pipeline

强大的产品管道

Disease Burden Of Huntington's In Developed Countries

发达国家亨廷顿舞蹈病的疾病负担

Market Restraint Analysis

Significant Challenges And Unmet Needs In Huntington's Disease Treatment

High Failure Rate In Clinical Trials

临床试验失败率高

Business Environment Analysis

商业环境分析

Swot Analysis; By Factor (Political & Legal, Economic And Technological)

Swot分析；按因素（政治和法律，经济和技术）

Porter's Five Forces Analysis

五力分析

Competitive Landscape

竞争格局

H. Lundbeck A/S

H.Lundbeck A/S

Teva Pharmaceutical Industries Ltd.

特瓦制药工业有限公司

Bausch Health Companies Inc.

博士后健康公司。

Hetero

异性

Lupin

羽扇豆

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC

Dr. Reddy's Laboratories Ltd.

Reddy博士的实验室有限公司。

Sun Pharmaceutical Industries Ltd.

太阳制药有限公司。

For more information about this report visit https://www.researchandmarkets.com/r/34rxn1

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/34rxn1

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是国际市场研究报告和市场数据的全球领先来源。我们为您提供有关国际和区域市场，关键行业，顶级公司，新产品和最新趋势的最新数据。